CTKB Cytek Biosciences, Inc.

Nasdaq cytekbio.com


$ 3.98 $ -0.16 (-3.87 %)    

Thursday, 16-Oct-2025 13:54:38 EDT
QQQ $ 600.60 $ -4.61 (-0.76 %)
DIA $ 461.02 $ -2.35 (-0.51 %)
SPY $ 661.86 $ -5.03 (-0.75 %)
TLT $ 91.34 $ 0.84 (0.93 %)
GLD $ 394.94 $ 3.79 (0.97 %)
$ 4.06
$ 4.13
$ 3.98 x 609
$ 4.00 x 700
$ 3.96 - $ 4.22
$ 2.37 - $ 7.63
439,507
na
516.53M
$ 1.08
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-13-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-01-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-17-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 09-02-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cytek-biosciences-announces-the-relocation-of-its-european-headquarters-to-a-new-facility-in-amsterdams-life-sciences-district

FREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operations and enhances service for ...

 cytek-biosciences-narrows-fy2025-sales-guidance-from-196000m-210000m-to-196000m-205000m-vs-198301m-est

Cytek Biosciences (NASDAQ:CTKB) narrows FY2025 sales outlook from $196.000 million-$210.000 million to $196.000 million-$205.00...

 cytek-biosciences-q2-eps-004-inline-sales-45602m-miss-46479m-estimate

Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This i...

 morgan-stanley-maintains-equal-weight-on-cytek-biosciences-lowers-price-target-to-7

Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight and lowers the price targe...

 goldman-sachs-maintains-sell-on-cytek-biosciences-lowers-price-target-to-3

Goldman Sachs analyst Matthew Sykes maintains Cytek Biosciences (NASDAQ:CTKB) with a Sell and lowers the price target from $...

 cytek-biosciences-lowers-fy2025-sales-guidance-from-20400m-21200m-to-19600m-21000m-vs-20443m-est

Cytek Biosciences (NASDAQ:CTKB) lowers FY2025 sales outlook from $204.00 million-$212.00 million to $196.00 million-$210.00 mil...

 cytek-biosciences-q1-eps-009-misses-004-estimate-sales-5193m-beat-4266m-estimate

Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $...

 stephens--co-reiterates-overweight-on-cytek-biosciences-maintains-6-price-target

Stephens & Co. analyst Mason Carrico reiterates Cytek Biosciences (NASDAQ:CTKB) with a Overweight and maintains $6 price...

 piper-sandler-maintains-overweight-on-cytek-biosciences-lowers-price-target-to-8

Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price targ...

 cytek-biosciences-sees-fy2025-sales-204000m-212000m-vs-21960m-est

Cytek Biosciences (NASDAQ:CTKB) sees FY2025 sales of $204.000 million-$212.000 million vs $219.60 million analyst estimate.

 cytek-biosciences-q4-eps-007-beats-005-estimate-sales-5748m-miss-5938m-estimate

Cytek Biosciences (NASDAQ:CTKB) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0....

 cytek-anticipates-2024-revenue-between-200m-201m-4-growth-over-2023-q4-revenue-expected-at-57m-58m-11-13-rise-from-q3-amid-15m-impact-from-stronger-usd

Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenu...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION